Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 2,566 shares at $140.72 ($361K) on 2024-01-31, disclosed to the SEC on 2024-02-02.
Scheduled sale ($361k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $140.72 | 1,283 | $181K | 50.0% |
| 2 | $140.72 | 1,283 | $181K | 50.0% |
| Total | $140.72 avg | 2,566 | $361K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |